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Chronic obstructive pulmonary disease (COPD) and cystic ﬁbrosis (CF) share molecular mechanisms that cause the
pathological symptoms they have in common. Here, we review evidence suggesting that hyperactivity of the EGFR/ADAM17
axis plays a role in the development of chronic lung disease in both CF and COPD. The ubiquitous transmembrane protease
A disintegrin and metalloprotease 17 (ADAM17) forms a functional unit with the EGF receptor (EGFR), in a feedback loop
interaction labeled the ADAM17/EGFR axis. In airway epithelial cells, ADAM17 sheds multiple soluble signaling proteins by
proteolysis, including EGFR ligands such as amphiregulin (AREG), and proinﬂammatory mediators such as the interleukin 6
coreceptor (IL-6R). This activity can be enhanced by injury, toxins, and receptor-mediated external triggers. In addition to
intracellular kinases, the extracellular glutathione-dependent redox potential controls ADAM17 shedding. Thus, the epithelial
ADAM17/EGFR axis serves as a receptor of incoming luminal stress signals, relaying these to neighboring and underlying cells,
which plays an important role in the resolution of lung injury and inﬂammation. We review evidence that congenital CFTR
deﬁciency in CF and reduced CFTR activity in chronic COPD may cause enhanced ADAM17/EGFR signaling through a defect
in glutathione secretion. In future studies, these complex interactions and the options for pharmaceutical interventions will be
further investigated.
1. Introduction
Airway epithelium, apart from providing a structural barrier
against microbes and inhaled particles, also plays an active
role in the ﬁrst line of inﬂammatory responses [1], and thus
emerged as a therapeutic target in chronic lung disease [2].
Airway epithelial cells respond dynamically to bacterial and
viral infections [3–5] or inhaled noxious particles by trans-
ducing inﬂammatory signals [6, 7]. They produce cytokines,
growth factors, and other inﬂammatory mediators to orches-
trate epithelial repair and adaptation and recruit a range of
inﬂammatory cells including neutrophils and macrophages
[1, 8, 9]. Importantly, airway epithelial cells also crosstalk
with the underlying connective tissue [10, 11].
This process normally leads to full resolution of inﬂam-
mation and tissue damage. However, in chronic lung disease,
exaggerated trans-signaling can lead to permanent changes
of tissue structure and loss of lung function, chronic inﬂam-
mation, and mucous metaplasia.
Despite their diﬀerent etiology, cystic ﬁbrosis (CF), a
congenital abnormality caused by mutations in a chloride
transporter, and chronic obstructive pulmonary disease
(COPD), caused by chronic exposure to airborne irritants,
share many common features in their pathology detailed in
the paragraphs below (Figure 1) [12–14]. Both diseases are
characterized by progressive and essentially irreversible lung
damage, chronic bronchitis, bacterial colonization, reduced
mucociliary clearance, and mucus plugging.
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This leads to the question whether these diseases, while
quite diﬀerent in many aspects, share common molecular
mechanisms and therapeutic targets (Figure 1) [15–17]. In
this review, we focus on a signaling pathway called the
EGFR/ADAM17 axis and its potential role in chronic lung
disease, in particular CF and COPD. Similarly, but outside
the scope of this review, other forms of chronic inﬂammatory
lung disease, including asthma, can be added to this list.
A disintegrin and metalloprotease 17 (ADAM17), a ubiq-
uitous sheddase formerly known as TACE (Figure 2), that
releases a broad spectrum of soluble biologically active
ligands from airway epithelial and myeloid cells is recognized
as an important transducer of airway epithelial cis- and
trans-signaling [18]. As detailed below, ADAM17 interacts
with the EGF receptor (EGFR), mainly through the shedding
of EGFR ligands, and conversely, EGFR is required for
ADAM17 activity, in a feedback signaling cascade labelled
the EGFR/ADAM17 axis. This system is highly sensitive to
various extracellular triggers, including cigarette smoke and
bacterial toxins, resulting in the enhanced shedding of a large
repertoire of growth factors, cytokines, and cytokine recep-
tors that are substrates of ADAM17. This in turn leads to
paracrine and autocrine receptor activation, which plays an
important role in the resolution of airway inﬂammation
and tissue damage.
In this review, we focus on the role of the epithelial
EGFR/ADAM17 signaling pathway that transmits signals
from luminal receptors towards underlying tissue (paracrine)
and epithelial cells (autocrine) (Figure 3), aﬀecting inﬂam-
mation and remodeling. However, EGFR and ADAM17 are
ubiquitously expressed, and also the expression of ADAM17
substrates is not limited to epithelial cells. Therefore, the
complete signaling cascade also includes ﬁbroblasts, smooth
muscle cells, and myeloid cells.
The relative contribution of the diﬀerent cell popula-
tions in the EGFR/ADAM17 signaling pathway in humans
is still under investigation. Current knowledge is largely
based on studies with conditional mutant murine models,
in which ADAM17 can be selectively ablated in speciﬁc
cell types. Knocking out ADAM17 in mesenchymal cells
did not produce a detectable developmental phenotype,
whereas epithelial ablation resulted in severe abnormalities
[19]. Horiuchi et al. showed that the epithelial EGFR/
ADAM17 axis plays a major role in tissue regeneration
during colonic inﬂammation and that loss of myeloid
expression does not have a major eﬀect. However, myeloid
ablation of ADAM17 does reduce the lethality of endotoxin
shock induced by intraperitoneal injection [20]. While these
studies give important insight in the basic architecture and
activity of this system, due caution is required when applied
to human tissues. In addition to obvious diﬀerences in archi-
tecture and function of human and mouse lungs, substrate
speciﬁcity and expression patterns of members of the
ADAM sheddase families and ligand interactions with
receptors will diﬀer.
We propose, based on evidence in the literature dis-
cussed below, that the molecular mechanism underlying
the development of CF and COPD lung disease may involve
abnormal activation of the epithelial ADAM17/EGFR axis.
To put this in perspective, we ﬁrst review CF and COPD
pathology and the unmet need in clinical intervention. Next,
we discuss the role of the EGFR/ADAM17 axis in lung
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Figure 1: Common features of CF and COPD. CF and COPD lung disease share many common clinical manifestations despite the
diﬀerences with respect to etiology. Mutations in the CFTR gene determine CF lung disease. Recently, CS has been shown to aﬀect CFTR
channel activity and this is recognized as a factor that may contribute to a CF-like phenotype in COPD. Thus, COPD has been recently
described as “acquired CF.”
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Figure 2: ADAM17 domain structure. ADAM17 is an atypical member of the ADAM family. It has additional disulﬁde bonds in the
metalloprotease domain, and it lacks two calcium binding sites in the disintegrin domain. The membrane proximal domain (MPD),
replacing the cysteine-rich and EGF-like domains, with a novel alpha/beta fold has a shorter cysteine-rich segment. The MPD has cysteine
residues determining the ADAM17 conformation (open/closed) and ADAM17 protease activity (active/inactive switch). The MPD is in
close proximity to the active site likely due to a C-shaped conformation of the extracellular part of mature ADAM17 [99]. ADAM17 lacks
an EGF-like domain, so the MPD is followed by the juxtamembrane region “conserved ADAM17 dynamic interaction sequence”
(CANDIS) involved in substrate recognition [162]. The trans-membrane region ends with a cytoplasmic tail with phosphorylation sites,
which are likely important for ADAM17 activity and traﬃcking [97–101].
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Figure 3: ADAM17 dependent paracrine and autocrine signaling. A disintegrin and metalloproteinase 17 (ADAM17), also known as a tumor
necrosis factor-α converting enzyme (TACE), is involved in the immune defense mechanisms mediated by epithelial cells. ADAM17 releases
extracellular domains of transmembrane proteins to produce soluble bioactive signaling proteins taking part in autocrine (activation of
receptors within the same epithelial cell layer) and paracrine signaling (activation of cellular receptors on underlying neighboring cells,
also termed transactivation). Among the ADAM17 substrates are (1) adhesion proteins (L-selectin, ICAM), (2) transmembrane mucins
(MUC-1), (3) membrane-bound cytokines (TNF-α), (4) growth factors (AREG) and other ligands of EGFR (TGF-α, EREG, HB-EGF, and
epigen), and (5) cytokine receptors (IL-6R, TNF-R). Ectodomain shedding provides the mechanism for autocrine and paracrine signaling.
IL-6R shed from epithelial cells transactivates gp130 on the underlying myoﬁbroblasts, whereas AREG shed from epithelial cells activates
EGFR on epithelial cells or on the underlying ﬁbroblasts. The ADAM17 inhibitor TIMP-3 inhibits the ADAM17 proteolytic activity.
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pathology, the molecular mechanisms involved, and poten-
tial therapeutic strategies.
2. Cystic Fibrosis: A Congenital Lung
Disease with an Early Onset
CF is an autosomal recessive lung disease caused by more
than 2000 diﬀerent mutations in the cystic ﬁbrosis trans-
membrane conductance regulator (CFTR) gene [21] with
approximately 80,000 patients worldwide. The most com-
mon CF mutation is the deletion of a phenylalanine at
amino acid position 508 in the NBD1 domain of CFTR
protein (F508del) [22]. The CFTR gene encodes a chloride
channel mainly expressed in the apical membrane of secre-
tory epithelial cells [23]. CFTR has a key role in maintaining
ion and water homeostasis in secretory epithelia [23]. Muta-
tions in CFTR cause a multiorgan CF disease aﬀecting the
lungs, intestine, pancreas, liver, sinuses, and reproductive
organs [24]. However, under present treatment, the main
morbidity and mortality among CF patients is due to lung
malfunction; consequently, most available and experimental
treatments aim to prevent the progression of CF lung disease
[25]. CFTR is also involved in transport of other anions,
for instance bicarbonate [26] and glutathione [27, 28].
Bicarbonate is crucial to normal expression of mucins that
in CF remain aggregated and poorly solubilized [29]. Gluta-
thione, as a natural antioxidant, reduces oxidative cellular
stress [30].
2.1. CF Lung Disease: An Early Disorder of Distal Airways.
Advances in imaging and monitoring of the respiratory
system in infant patients have revealed that severe CF lung
pathology starts early in childhood and progresses irre-
versibly over time [31–33]. This early onset of lung abnor-
malities includes bronchiectasis, diagnosed thickening and
dilation of the bronchial walls, air trapping, and atelectasis
(partial collapse of the lung) [34, 35]. These symptoms
occur simultaneously with reduced mucociliary clearance
and mucus plugging [36]. Quantitative and standardized
tracking of early lung disease progression in infants with
CT scans is pursued to advance the comparative analysis
and provide the evaluation of the treatment [37, 38].
In a recent micro CT and histological study of end-stage
CF lungs, the dilatation and obstruction of distal airways and
a severe reduction in the number of functional terminal
bronchioles were clearly documented for the ﬁrst time. This
conﬁrms that obstruction and remodeling of peripheral air-
ways is a prominent feature in CF lung disease and therefore
are prime targets of experimental therapy [14]. CF mouse
models [39] and large CF animal models, like pig [40] and
ferret [41], are helpful in the investigation of the mechanism
involved in this early onset of CF lung disease and interven-
tion therapy, but all have considerable limitations due to spe-
cies variation. In addition to state-of-the-art clinical and
biomarker studies, there is an urgent need for the develop-
ment of organotypic and personalized cell culture models
in which the complex molecular and cellular interactions
involved in CF lung pathology can be studied.
2.2. Mucociliary Transport. In healthy subjects, mucociliary
clearance requires CFTR-dependent balanced ﬂuid and
proper mucus secretion from surface cells and subepithelial
glands. However, high mucus viscosity in CF is caused by
reduced CFTR-dependent bicarbonate secretion, required
for proper expansion of secreted mucus molecules [42, 43].
Furthermore, CF patients have intrinsically impaired ciliary
beat frequency (CBF), which is not only dependent on
CFTR-mediated bicarbonate transport but also regulated by
soluble adenyl cyclase (sAC) [44]. Together, this impairs
eﬀective clearance of bacteria and inhaled particles in CF
lung [45, 46]. Importantly, reduced mucociliary clearance is
also a feature of COPD, which may be in part related to
reduced CFTR activity in smokers’ lungs [47].
2.3. Bacterial Infection and Inﬂammation. Airway epithelial
cell cultures from CF patients have reduced air-surface liquid
(ASL) height, presumably due to defective CFTR-dependent
ﬂuid secretion [48]. Additionally, as a consequence of
reduced bicarbonate secretion, CFTR deﬁciency abnormally
acidiﬁes ASL [49] which impairs bacterial killing [50, 51],
inhibits the activity of ASL antimicrobials [52], and increases
ASL viscosity of newborn CF piglets [45].
Impaired bacterial killing and mucociliary clearance in
CF lungs together facilitate colonization with opportunistic
pathogens generally harmless in normal individuals [53].
Despite activation of inﬂammatory responses mediated by
the innate and cellular immune system, eradication of bacte-
rial infection is impaired in CF lungs. Instead, bacterial
infections induce a massive and chronic recruitment of neu-
trophils, which ultimately contributes to irreversible airway
remodeling, observed as air trapping, bronchiolar obstruc-
tion, bronchiectasis, and loss of function [14].
2.4. Sterile Lung Inﬂammation in CF.While chronic infection
is undoubtedly a major issue in CF pathology, it remains con-
tested whether inﬂammation in CF only results from bacte-
rial infection or is an intrinsic property of CFTR-deﬁcient
mucosa. Lung disease and inﬂammation is already observed
in CF infants before bacterial colonization, suggesting that
inﬂammation may precede infection in CF lung. Several
reports argue that bacterial infections are indispensable
to inﬂammatory responses, in CF humans [54] or CF pig
[55]. However, unchallenged CF mutant mice show inﬂam-
mation [56]. Also, in the CF ferret model, inﬂammation
and tissue remodeling do not require previous bacterial
infections [57]. Such sterile inﬂammation may be caused
by functional abnormalities in CF myeloid cells, in particular
macrophages [58, 59], dendritic cells [56], and neutrophils
[60] or may be primarily related to abnormal cytokine signal-
ing by CFTR-deﬁcient airway epithelial cells. Several studies
suggest that CFTR malfunction leads to overexpression of
growth factors and proinﬂammatory cytokines as a cell-
autonomous defect [61–63]
Due to the early onset of CF lung disease and its irre-
versible nature, it is clear that CF patients require early
intervention therapy [32]. Excessive lung inﬂammation
and tissue remodeling observed in CF may be an inherent
property of CFTR-deﬁcient lung mucosa. Therefore, it is
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important to establish the mechanisms involved in CFTR-
related inﬂammatory responses and whether alleviation of
inﬂammatory responses is beneﬁcial in the management
of CF lung disease [64].
3. Strategies of CF Therapy
CF lung disease is still the main cause of morbidity and mor-
tality in CF despite intensive treatment [14]. Indirect phar-
macological management focuses on anti-inﬂammatory
agents [65, 66], antibiotics [67], and mucolytic agents [68].
Direct pharmacological management of CF disease intends
to restore the functional expression of mutated CFTR at the
plasma membrane by correcting its folding and gating defect
[69]. In 2015, the FDA approved ORKAMBI® for homozy-
gous F508del CFTR patients, comprising ﬁfty percent of the
CF population, the combination of CFTR corrector lumacaf-
tor (VX-809) and potentiator ivacaftor (VX-770) in one pill.
This therapy improves lung function in patients homozygous
for the F508del mutation, although modestly and not in all
patients [25, 70]. Therefore, further investigations are in
progress to ﬁnd more eﬀective compounds [71, 72]. So far,
the eﬀects of correctors and potentiators on infections and
the release of inﬂammatory mediators have not been broadly
investigated in clinical studies. Rowe et al. showed that
ivacaftor reduces P. aeruginosa isolated from CF patients
carrying a CFTR gating mutation after 6 months treatment.
However, the free neutrophil elastase and other inﬂamma-
tion markers like IL-1β, IL-6, and CXCL8 (IL-8) in sputum
samples remained unchanged [73]. Therefore, anti-inﬂam-
matory, antibacterial, and other additional therapies are still
important targets of investigation [74].
In summary, recent breakthroughs in the development of
small-molecule compounds targeting the mutant CFTR pro-
tein have raised hope to ﬁnd a cure for CF. However, the
presently available CFTR correctors and potentiators are
not suﬃciently eﬀective in a majority of CF patients, and
the search for new compounds and additional therapies is
still highly relevant. Though CF is considered monogenetic,
the downstream responses to CFTR deﬁciency and responses
to therapeutic intervention are highly variable in the popula-
tion. The perfect corrector and potentiator combination tai-
lored to the individual patient, supported by additional
anti-inﬂammatory medication (personalized medicine),
would likely be the best solution.
4. COPD Is Acquired CF?
Chronic obstructive pulmonary disease (COPD) is the 5th
ranking cause of death worldwide. Usually, COPD is charac-
terized by chronic bronchitis and emphysema [75]. Similar to
CF, bronchiectasis [76] and peripheral airway thickening are
also observed, similar to early and advanced CF lung disease
[77]. Some individuals develop lung disease dominated by
emphysema, while others exhibit chronic bronchitis. This
heterogeneous phenotype likely reﬂects the contribution of
multiple pathogenic mechanisms and the genetic heteroge-
neity of the population. Once COPD starts to develop, it
tends to worsen over time, and so far its progress cannot be
controlled eﬀectively in most patients. The most prominent
etiological factor leading to COPD is cigarette smoke, and
also exposure to fumes, chemicals, and dust [78]. Although
COPD and CF diﬀer in primary cause, the spectra of the
pathological events overlap considerably (Figure 1). Chronic
bacterial infections with frequent exacerbations are observed,
including colonization with the opportunistic pathogen
Pseudomonas aeruginosa, which are also a hallmark of CF
lung disease. However, the strains adapted to COPD lungs
appear to diﬀer from CF, suggesting that although similar
mechanisms are involved, the luminal milieu in COPD dif-
fers from that in CF [79]. Both diseases are characterized by
excessive mucus production and insuﬃcient clearance, lead-
ing to lower airway obstruction and chronic neutrophilic
inﬁltration. In CF and COPD, airway surface liquid (ASL)
dehydration and viscous mucus secretion impair mucociliary
clearance, causing chronic inﬂammation and facilitating
recurrent infections [80]. A wide variety of proinﬂammatory
mediators in COPD (like CXCL8, IL-6, and CCL18) overlap
with CF-related mediators [74, 81]. There are also parallels
on the cellular level which include goblet cell metaplasia,
hyperplasia of myoblasts, and extensive extracellular matrix
production [17].
The broad spectrum of common features and events
observed in CF and COPD encouraged researchers to seek
common factors for these diseases. Cigarette smoke decreases
CFTR mRNA expression and reduces CFTR protein level
through accelerated degradation, leading to impaired muco-
ciliary clearance and depleted ASL in vitro and in vivo
[82–84]. Mice treated with cigarette smoke show reduced
CFTR activity that can be corrected by the cAMP agonist
and phosphodiesterase inhibitor roﬂumilast, restoring CFTR
activity [85]. Furthermore, macrophage phagocytosis and
CFTR activity are impaired by cigarette smoke [86]. Simi-
larly, CFTR-deﬁcient macrophages are abnormal [59]. These
are short-term and transient eﬀects in normal cells, which do
not explain the progressive inﬂammatory lung disease of
COPD patients that stopped smoking. However, several
reports show that the abnormal characteristics of COPD epi-
thelial cells, including reduced CFTR expression in situ, per-
sist in culture [87], probably due to a combination of genetic
factors and epigenetic imprinting. Furthermore, COPD
patients, smokers, and former smokers show signs of persis-
tent reduced CFTR function in upper and lower airways,
which may contribute to chronic lung disease [80]. Conse-
quently, several authors described COPD as an “acquired
CF” through e reduction of CFTR activity, suggesting that
these diseases with diﬀerent etiology have common thera-
peutics options [16, 17, 80, 85].
5. Strategies of Therapy in COPD
Based on the previous arguments, CFTR potentiators and
correctors, such as those developed to enhance the activity
of mutant CFTR, could be useful to treat COPD. However,
small molecules designed to target mutant CFTR traﬃcking
and gating may actually reduce activity of normal CFTR
upon chronic treatment [88]. Nevertheless, further screening
and testing of novel compounds in a personalized setting
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may lead to improvement of CFTR function and reduction of
lung disease in COPD patients.
Chronic inﬂammation is recognized as the major patho-
physiological mechanism of COPD progression, with molec-
ular targets overlapping those of CF (e.g., IL-6, CXCL8, and
CCL18) [74]. Thus, chronic airway inﬂammation remains
an important therapeutic target in COPD management. It
often persists after cessation of smoking, suggesting that apart
from the role of CFTR also epigenetic changes in the res-
olution of inﬂammation likely play a role [89, 90]. Presently,
several compounds targeting inﬂammatory responses in
COPD are under investigation [91, 92], though none of these
have been shown to be beneﬁcial in COPD patients as yet.
Therefore, as in CF, COPD is a complex multifactorial
disease, with large variation in the patient population due
to largely undeﬁned genetic and environmental factors. A
personalized approach using multiple treatments is likely
required, but a robust trial strategy is elusive. The advance
of personalized 3D culture models, combining induced
stem cell (iPSC) and gene editing [93] with microﬂuidics
(“lung-on-a-chip”) technology [94] may allow us to proceed
towards better treatment.
6. Epithelial EGFR/ADAM17 Axis: A Potential
Therapeutic Target in CF and COPD
Lung Disease
The design of anti-inﬂammatory agents aims mainly to
decrease the neutrophil inﬂux into the lung and concomitant
inﬂammatory responses [8]. The importance of airway epi-
thelial cells in inﬂammatory responses has been recognized
for decades, but the signaling network is still under intense
investigation [1, 95]. Airway epithelium serves as the ﬁrst
barrier and acts as defense against daily inhaled air pollutants
and microbes by mucociliary clearance and secretion of a
range of cytokines, cytokine receptors, growth factors,
growth factor receptors, and antimicrobial peptides [1, 96].
Airway epithelial cells not only release inﬂammatory media-
tors to ASL but also signal to the underlying tissues (myo-
cytes or ﬁbroblasts). One of the mechanisms controlling
paracrine and autocrine proinﬂammatory and proﬁbrotic
signaling in airway epithelium is the EGFR/ADAM17 axis.
A disintegrin and metalloproteinase 17 (ADAM17), also
known as a tumor necrosis factor-α converting enzyme
(TACE), is a transmembrane protein with proteolytic activ-
ity. It releases extracellular domains of its substrates, gener-
ally transmembrane proteins, to produce soluble bioactive
signaling proteins, in a process called shedding. Mature
ADAM17 consists of several functional domains (Figure 2),
an extracellular metalloprotease domain (catalytic), a disin-
tegrin domain, a membrane proximal domain (MPD) rich
in cysteine residues, and a “conserved ADAM-seventeen
dynamic interaction sequence” (CANDIS). Unlike other
ADAM family members, it lacks an EGF-like domain
[97–101]. These extracellular domains are connected to a
transmembrane region and cytoplasmic tail with phos-
phorylation sites that likely are involved in ADAM17 acti-
vation or traﬃcking (Figure 2).
Ectodomain shedding mediated by the metalloprotease
domain of ADAM17 provides a mechanism for initiation
or inhibition of autocrine/paracrine signaling. So far, 76
proteins have been identiﬁed as substrates of ADAM17
[18]. They encompass membrane-bound cytokines (TNF-
α), cytokine receptors (IL-6R, TNF-R), growth factors, in
particular ligands of EGFR (TGF-α, AREG, EREG, HB-
EGF, and epigen), adhesion proteins (L-selectin, ICAM-1),
and transmembrane mucins (MUC-1). The shed soluble
forms of these proteins are bioactive transducers of cell sig-
naling via activation of cellular receptors on underlying
neighboring cells (transactivation/paracrine activation), but
they also are involved in activation of the shedding cells
and neighboring cells (autocrine activation) (Figure 3).
Because most of the epidermal growth factor receptor
(EGFR) ligands are cleaved by ADAM17, this sheddase has
emerged as an important transducer of the airway epithelial
autocrine and paracrine EGFR signaling (Figure 3). EGFR
and ADAM17 are both involved in the broad spectrum
of events that is characteristic of both CF and COPD lung
disease, like excessive mucus expression [102–104], cyto-
kine secretion [105], airway epithelial cell wound healing
[106, 107], abnormal airway proliferation [108], mainte-
nance of barrier integrity, and progressive lung tissue scar-
ring [109]. They both are activated upon bacterial or viral
infection and during inﬂammation [3, 5, 110]. While this
is an eﬀective and necessary response, it is suggested that
exaggerated airway epithelial signaling in the chronic state
may enhance inﬂammation and may lead to permanent
damage to the lung structure.
EGFR functions as a sensor of airway epithelial integrity
[111]. When cells have intact tight junctions, EGFR is not
activated. But disruption of the epithelial cell integrity, either
by mechanical injury or cytokine treatment (TNF-α/IFN-γ),
leads to EGFR phosphorylation and concomitant inhibition
of protein phosphatase 2A activity [112]. Cigarette smoke
exposure of diﬀerentiated HBEC also leads to damage of
the lung tissue observed as destruction of epithelial cell
integrity, loss of E-cadherin/β-catenin complex, and disap-
pearance of cilia [113]. This coincides with phosphorylation
and perinuclear traﬃcking of EGFR [113] suggesting the
importance of EGFR in maintenance of epithelial cell barrier
integrity. The response of ADAM17 to loss of pulmonary
epithelial cell integrity has been also shown by neuregulin-1
(NRG-1) shedding and concomitant activation of human
epidermal growth factor receptor-2 (HER2) [114]. This raises
the question whether and how EGFR and ADAM17 cooper-
ate in sensing responses to airway injury.
6.1. EGFR and ADAM17 Are Important in Lung Development.
Inactivation of ADAM17 by deletion of the zinc binding
domain through homologous recombination in mice led
to severely hypoplastic lungs at birth, reduced branching
morphogenesis and alveolar development, impaired epithe-
lial cell proliferation, and diﬀerentiation and delay in vascu-
logenesis [115]. Due to the early mortality of ADAM-KO
mice, several alternative ADAM17 mouse models have been
developed, with reduced activity (hypomorphic) or condi-
tional mutants [116]. Conditional knockout ADAM17 mice
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can serve as a model to investigate the role of ADAM17 in
organogenesis, in speciﬁc cell types, and in inﬂammatory
responses and tissue remodeling [20, 117]. Induced dys-
function of ADAM17 (ADAM17ﬂox/ﬂox SPC-rtTA TetO-
Cre) in developing lung epithelial cells reduced saccular
formation, cell proliferation, and lung epithelial cell diﬀer-
entiation, but the mice were born without severe respira-
tory distress [19]. Knocking out the gene in mesenchymal
cells using a Dermo1-Cre transgene did not produce a
detectable phenotype [19]. This suggests that epithelial,
but not mesenchymal, ADAM17 plays a prominent role
in lung development.
Other studies show that conditional knockout mice
(ADAM17ﬂox/ﬂox with R26Cre-ER) treated with human
neutrophil elastase have attenuated goblet cell metaplasia in
comparison to the wild-type mice [118], suggesting that
ADAM17 is involved in injury-induced airway metaplasia.
Similar to ADAM17-KO mice, EGFR-KO mice survive for
up to 8 days after birth and suﬀer from impaired epithelial
development in several organs, including the lungs, underlin-
ing the need of a functional EGFR/ADAM17 axis for proper
functioning and development of lung epithelium [119].
6.2. ADAM17 and EGFR Crosstalk. ADAM17 works in asso-
ciation with the tyrosine kinase receptor EGFR ﬁrstly by
shedding most of its ligands, including AREG, HB-EGF,
TNF-α, EPGN (epigen), and EREG (epiregulin) [18], result-
ing in activation of EGFR. In humans, only two EGFR
ligands, EGF and betacellulin, are shed by ADAM10 [120,
121], a close relative of ADAM17 [18]. Crosstalk of ADAM17
and EGFR in inﬂammatory signaling transduction is further
deﬁned by the establishment of a positive ADAM17/EGFR
feedback loop likely involving activation of ADAM17 via
the EGFR/MAPK pathway [110, 122] (Figure 4). The exact
molecular mechanism of this feedback signaling has not been
ﬁrmly established. Moreover, ADAM17 regulates transcrip-
tion of EGFR mRNA by cleavage of Notch1 and thus
increases EGFR expression in a non-small lung carcinoma
cell line [123], providing another positive feedback mecha-
nism of the EGFR/ADAM17 axis (Figure 4).
In diﬀerentiated primary bronchial epithelial cells
(HBEC-ALI), inhibitors of EGFR and of ADAM17
completely abolished ADAM17 substrate shedding as well
as EGFR-dependent CXCL8 mRNA induction [87], illustrat-
ing the strong interrelationship between the key elements of
the EGFR/ADAM17 axis (Figure 4).
6.3. The Role of ADAM17 and EGFR in Balanced Regulation
of Lung Inﬂammation and Regeneration. ADAM17 is
expressed in human bronchial epithelial cells in the large
and small bronchi, in lung smooth muscle cells, lung muscu-
lar vessels, alveolar macrophages, perivascular leukocytes,
and lung endothelial cells. It has been long recognized as an
important regulator of lung tissue homeostasis [116, 124,
125], pro- and anti-inﬂammatory responses [18], and tissue
regeneration [122, 126, 127].
The anti- and proinﬂammatory properties of the EGFR/
ADAM17 signaling pathway are context and cell type depen-
dent [18]. For instance, in airway epithelial cells, ADAM17
together with EGFR induces mRNA expression and protein
release of CXCL8, a neutrophil chemotactic factor that pro-
motes inﬂammation [7, 87, 105]. However, by shedding
TNF receptor type 2 (TNFR2) [128], which antagonizes
TNF-α, ADAM17 exhibits also anti-inﬂammatory properties
[129]. Thus, it is likely that the type of stimulus and substrate
selection determine the eﬀect of the EGFR and ADAM17
activity [130–132].
EGFR/ADAM17 signaling in tissue regeneration encom-
passes wound healing [122], proliferation [126, 127], diﬀer-
entiation [19, 133], and cell migration [134]. Due to the
involvement of EGFR/ADAM17 paracrine and autocrine sig-
naling in several lung disorders [109, 116], modulation of
ADAM17 and EGFR activation in both COPD and CF is
important, to keep the balance between anti-inﬂammatory
processes and promotion of inﬂammation, and also between
regeneration and excessive tissue remodeling. Indeed, we
recently found that cigarette smoke induced shedding of
the ADAM17 substrate amphiregulin (AREG), and IL-6R
was enhanced in diﬀerentiated bronchial cells in culture
obtained from COPD patients compared to non-COPD, sug-
gesting that epigenetic factors controlling the activity of the
ADAM17/EGFR axis are aﬀected in COPD [87].
6.4. Release of Cytokines, Growth Factors, and Mucins
Depends on ADAM17/EGFR Signaling. External stress factors
like oxidative stress, viral and bacterial toxins, and CS expo-
sure activate the ADAM17/EGFR signaling pathway. Patho-
gens inhaled into the airways, or exposure to other stimuli,
activate Toll-like receptors (TLR) [135–137] and G-coupled
receptors (GPCR) [138] that crosstalk with downstream
ADAM17/EGFR signaling. As a result of cigarette smoke
extract exposure, secretion of downstream proinﬂammatory
cytokines including CXCL8 [7, 139], growth factors (TGFα,
ADAM17
ADAM17-P
AREG
EGFR
MEK1/2
ERK1/2
Notch1
EGFR mRNA
Figure 4: The ADAM17/EGFR axis. The EGFR/ADAM17
positive feedback loop likely involves activation of ADAM17 via
the EGFR/MAPK pathway and direct interaction of ERK1/2
with ADAM17. Additionally, by cleavage of Notch1 from a non-
small lung carcinoma cell line ADAM17 regulates transcription
of EGFR mRNA and increases EGFR expression on the cell
surface, providing another mechanism contributing to positive
feedback regulation.
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AREG, and HB-EGF) [87, 105], cytokine receptor IL-6R [87],
mucins (MUC5AC), and phosphorylated MUC1 is induced
in an ADAM17/EGFR-dependent manner [103, 113, 140,
141]. This cascade of events involves mitogen-activated pro-
tein kinases (MAPK), MAPK1 (ERK1), MAPK2 (ERK2), and
p38-MAPK [3, 142]. Upon activation of the ERK or p38
MAPK pathway, ADAM17 dissociates from an endogenous
extracellular tissue inhibitor of metalloproteinase-3 (TIMP-
3) [143-145], accumulates on the cell surface [146, 147],
and induces release of TGF-α [146]. Acrolein, an active com-
ponent of cigarette smoke, which induces MUC5AC mRNA
in an ADAM17 and EGFR dependent manner, decreases
TIMP-3 transcript levels, also suggesting a role of TIMP-3
in ADAM17 activation.
6.5. CFTR Deﬁciency Aﬀects the EGFR/ADAM17 Axis. Sev-
eral lines of evidence suggest that CFTR deﬁciency aﬀects
the activity of the EGFR/ADAM17 axis. F508del CFTR
mutant mice respond diﬀerently from normal to airway
injury by naphthalene [148]. A week after injury, we
observed a signiﬁcantly enhanced mRNA expression of
amphiregulin (AREG) compared to normal [149]. AREG
mRNA expression is dependent both on ADAM17 and
EGFR activity in human bronchial epithelial cells [87], sug-
gesting a link between CFTR deﬁciency and EGFR/ADAM17
activity during resolution of airway injury. Furthermore,
inhibition of CFTR with a small molecule (inh-172) in
NCI-H292 cells reportedly activates CXCL8 production in
an EGFR/ADAM17-dependent way [61]. However, the rela-
tionship between ADAM17/EGFR signaling and CFTR deﬁ-
ciency is still poorly understood and may involve a variety of
mechanisms [150].
Exaggerated responses mediated by the EGFR/ADAM17/
MAPK pathway have also been reported in CFTR-deﬁcient
cells compared to CFTR expressing counterparts. The
CFTR-deﬁcient cell line IB3 produces more CXCL8 than an
isogenic CFTR-expressing cell line. The CFTR-deﬁcient cell
line CuFi-1 produces more CXCL8 in response to heat-
inactivated P. aeruginosa than a non-CFTR-deﬁcient cell line
(NuLi-1), and this involves EGFR phosphorylation and
ERK1/2 activation [151]. Most of these studies use undiﬀer-
entiated, submerged immortalized cell lines [152], compare
genetically diverse cell lines (like CuFi and NuLi or IB3 and
C38 cells) [61, 151, 153, 154], or use a CFTR inhibitor [61]
with reported oﬀ-target eﬀects [155]. Further studies in pri-
mary human bronchial epithelial cells in air-liquid interface
culture, and models that allow comparison of genetically
identical populations in parallel, including CFTR-deﬁcient
and corrected induced pluripotent stem cells (iPSC) and
inducible CFTR-expressing CFBE cells, are currently per-
formed to further support the notion that CFTR is involved
in the activity of the EGFR/ADAM17 axis and may contrib-
ute to abnormal resolution of injury and inﬂammation in
CF lung disease.
6.6. Redox Potential: A Possible Link between CFTRDeﬁciency
and ADAM17/EGFR Signaling? The intra- and extracellular
redox potential changes in response to physiological pro-
cesses and in pathophysiological conditions [156]. Reactive
oxygen species (ROS), produced during cellular stress [74],
are an important regulator of redox state and they are also
involved in activation of the EGFR/ADAM17 signaling path-
way, aﬀecting TGF-α and AREG release and mucin expres-
sion [103, 104, 135]. Some studies point towards the role of
NADPH oxidases (NOX), in particular dual oxidase 1
(DUOX1) [104, 135, 157] or dual oxidase 2 (DUOX2)
[136], which produce ROS at an extracellular or possibly
intravesicular domain. ATP-mediated DUOX1 activation
involves a TGF-α/ADAM17/EGFR/ERK signaling pathway
[157]. Recent studies indicate a role of DUOX1 in allergen-
dependent SRC/EGFR activation in airway cells [158]. How-
ever, the mechanism by which ROS aﬀect EGFR/ADAM17
signaling in intact airway cells is likely highly complex and
still remains not well understood.
ROS do not only aﬀect receptors, phosphatases, and
kinases in the ADAM17/EGFR pathway, but ADAM17
[159] and EGFR [160] themselves are redox-sensitive pro-
teins. EGFR has intracellular cysteine residues in the active
site that are targets of ROS and determine EGFR kinase
activity, likely through association of EGFR with NADPH
oxidase, NOX2 [160]. ADAM17 activity is regulated by thiol-
disulﬁde isomerization in the extracellular MPD domain
mediated by protein disulﬁde isomerase (PDI), an oxidore-
ductase sensitive to redox changes [161]. PDI, by direct inter-
action with the membrane proximal domain (MPD) [159],
changes the disulﬁde bridge pattern and thus the conforma-
tion of the extracellular protease domain from open active
to closed inactive state leading to the inhibition of ADAM17
activity (Figure 5) [101, 162]. Redox-dependent conforma-
tional changes likely make ADAM17 sensitive to the extracel-
lular redox potential [159].
Since CFTR deﬁciency is thought to increase ROS levels
[163], which would activate ADAM17 and EGFR [122] and
inactivate protein phosphatases [164], we propose that redox
signaling is a plausible link between EGFR/ADAM17 activity
and CFTR deﬁciency. CFTR deﬁciency may change the
extracellular redox potential to more oxidized in airway,
because CFTR is involved in epithelial glutathione transport
at the apical membrane [27, 165], which serves as a natural
antioxidant [30]. This would in turn enhance the activity of
ADAM17 through the mechanism illustrated in Figure 5.
Polymorphisms in the glutathione pathway are modiﬁers of
CF lung pathology, emphasizing the importance of this path-
way [166]. Further studies are required to establish the rela-
tionship between glutathione transport, extracellular redox
potential, and the activity of the EGFR/ADAM17 axis in CF
airways. This can be achieved by application of ﬂuorescent
protein redox probes that can be expressed in diﬀerent cellu-
lar compartments [156] in advanced airway culture models.
7. Role of Amphiregulin in EGFR/ADAM17-
Dependent Lung Disease
One of the prominent ADAM17-dependent EGFR agonists
produced ubiquitously by the human lung is amphiregulin
(AREG) [167] by human airway epithelial cells [87, 105],
smooth muscle cells [168], and ﬁbroblasts [111]. AREG is
also expressed by inﬁltrating and resident lung myeloid cells,
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including activated macrophages [169], eosinophils [170],
dendritic cells [171], neutrophils [172], and mast cells
[173]. Human AREG is synthetized as an N-glycosylated
transmembrane precursor (50 kDa)[174] with a basolateral
sorting motif [175] and shed mainly by ADAM17 [110]. Pro-
teolytic cleavage of the AREG extracellular domain releases
several AREG-soluble forms, predominantly an α-N-glyco-
sylated 43 kDa form [174], which is one of the EGFR ligands,
with lower aﬃnity to EGFR than EGF and TGF-α.
7.1. AREG Is Induced in Lung Disease. AREG is involved in
inﬂammation and repair responses through autocrine and
paracrine activation of EGFR, and generally induced in lung
disease [176]. In CF sputum samples, elevated levels of AREG
have been shown in airway blood neutrophils [172]. In lung
biopsies from asthma patients, more AREG is expressed than
in healthy controls [167]. Other studies showed that in
sputum of asthma patients AREG is upregulated only during
an acute attack [177], suggesting its role in quick cellular
responses to the triggers. Increase of AREG in sputum
samples from children with asthma negatively correlates
with lung function [178] and positively correlates with the
number of eosinophils [179, 180].
Epithelial secretion of AREG in situ has not been investi-
gated in CF and COPD in comparison to controls. However,
Zuo et al. reported enhanced AREG expression in smoking-
induced airway lesions [181], and we observed a stronger
AREG shedding response to cigarette smoke in cultured
airway cells from COPD patients compared to normal [87]
suggesting a possible involvement in the progression of lung
disease. Current studies are aimed at elucidating the role of
CFTR deﬁciency in AREG shedding.
7.2. Regulation of AREG Transcription and Shedding. In vitro,
AREG mRNA expression and protein release are induced
upon exposure to diﬀerent stress factors like histamine
[167], diesel exhaust particles [6], cigarette smoke extract
exposure [182], cigarette smoke [87], and rhinoviruses [3].
Also, AREG protein secretion is dependent on the EGFR/
MAPK pathway in an airway epithelial cell line treated with
particulate matter [183]. In diﬀerentiated primary airway
cells, CS induction of AREG mRNA levels is abolished by
ADAM17 and EGFR inhibitors, consistent with a prominent
role of the EGFR/ADAM17 axis in AREG signaling and
mRNA synthesis [87].
7.3. AREG Aﬀects Mucus and Cytokine Secretion in
Asthmatic Patients. In asthmatic patients, AREG produced
by mast cells enhances mucus production [184]. AREG-
dependent MUC5AC mRNA level induction has been
shown upon exposure to particulate matter in NCI-H292
cells [185] and diﬀerentiated primary airway cells NHBE-
ALI [177]. AREG-dependent secretion of MUC5AC, TGF-
β1, and CXCL8 was also observed in epithelial cell line cul-
ture supernatants [179]. All these ﬁndings suggest an
important role of AREG in mucus secretion and cytokine
release in airway epithelial cells.
7.4. AREG in Paracrine Signaling and Tissue Remodeling. In
addition to its role in epithelial proliferation and diﬀerentia-
tion (autocrine), AREG is also involved in ﬁbrotic and
inﬂammatory responses (Figure 3). Conditioned media from
AREG-stimulated airway epithelial cells induced expression
of CXCL8, VEGF, COX-2, and AREG in human airway
smooth muscle cells, providing proof for paracrine crosstalk
between epithelial cells and connective tissue in an AREG-
dependent manner [168](Figure 6). Inhibition of AREG or
EGFR in TGF-β1-stimulated lung ﬁbroblasts diminished
AREG-dependent ﬁbroblast proliferation, expression of α-
smooth muscle actin and collagen [186], strongly suggesting
a role of EGFR/ADAM17/AREG signaling in pulmonary
ﬁbrosis in vivo.AREGstimulation also induces airway smooth
muscle cell proliferation, which leads to airway remodeling
in vivo [180].
These data together suggest that exaggerated and chronic
AREG release may contribute to mucus plugging, excessive
Closed, inactive ADAM17 conformation Open, active ADAM17 conformation
Reduced environment
Oxidized environment
PDI
PDI
Figure 5: ADAM17 is a redox-sensitive protein. The ADAM17 membrane proximal domain (MPD), which is in close proximity to the active
site, is sensitive to extracellular (or intravesicular) redox changes. This redox-sensitive ADAM17 activity is regulated by thiol-disulﬁde
isomerization mediated by protein disulphide isomerase (PDI), an oxidoreductase sensitive to redox changes. PDI changes the disulﬁde
bridge pattern and thus the conformation of the extracellular protease domain from an open active to a closed inactive state, by
direct interaction with the membrane proximal domain (MPD), leading to the inhibition of ADAM17 proteolytic activity. Redox
sensitive conformational changes likely make ADAM17 sensitive to the extracellular redox potential, which is dependent on glutathione
(GSH/GSSH) and ROS.
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inﬂammation, and tissue remodeling in CF and COPD.
Therefore, the EGFR/ADAM17/AREG signaling pathway is
a potential therapeutic target to regulate both inﬂammation
and lung cell proliferation in COPD and CF. However,
AREG is only one of the many players involved in the auto-
crine and paracrine signaling leading to lung pathology.
There is no available literature presenting intervention in
AREG function in clinical trials.
8. Role of IL-6R in Human Lung Inflammation
and Tissue Regeneration
Another prominent ADAM17 substrate involved in lung dis-
ease is the IL-6 coreceptor IL-6R. In “classic” signaling, this
transmembrane receptor type I binds to IL-6, which evokes
an association with a homodimer of signal transducing gly-
coprotein, gp130. This trimer dimerizes to form a hexameric
complex composed of IL-6, IL-6R, and gp130 [187]
(Figure 6). Alternatively, the extracellular domain of IL-6R
can also evoke a trans-signaling cascade, when it is shed by
ADAM17, producing a soluble form (sIL-6R) (Figure 6)
[188] or ADAM10 [188–190]. sIL-6R can be also generated
by alternative splicing of IL-6R mRNA [191–193]. How-
ever, data suggest that shedding rather than the alternative
splicing takes part in trigger-induced generation of the
sIL-6R [128]. Indeed, we observed that in primary bron-
chial epithelial cells in air liquid culture, cigarette smoke
enhanced ADAM17-dependent sIL-6R shedding but not
the production of the alternatively spliced mRNA [87].
Both the alternatively spliced form and the shed form of
sIL-6R can create functional complexes with IL-6 (IL-6/
sIL-6R) [194], mediating a transfer of stress responses
from epithelial cells to underlying mesenchymal and mye-
loid cells, involved in tissue remodeling and inﬂammation
(trans-signaling, Figure 6).
IL-6 activated membrane bound IL-6R has anti-inﬂam-
matory, antiapoptotic, and regenerative properties [128,
195–198]. In contrast, trans-signaling mediated by IL-6/sIL-
6R complexes binding to gp130 is thought to maintain
inﬂammation and promote inﬂammation-associated cancer
[128, 195, 199, 200] (Figure 6).
Importantly, IL-6R expression is not ubiquitous, but
restricted to speciﬁc cell types, such as lymphoid cells, hepa-
tocytes, and airway epithelial cells [4, 128, 201, 202]. How-
ever, cells that do not express IL-6R but do express gp130
can still transduce IL-6 signals via binding of IL-6/sIL-6R
complexes in trans. Thus, smooth muscle cells and endothe-
lial cells are responsive to IL-6 through IL-6/sIL-6R trans-
signaling provided by epithelial cells [203, 204] (Figure 6).
The role of IL-6R in CF and COPD has not been studied
in detail. In COPD patients, elevated levels of IL-6R have
been observed in peripheral blood leukocytes [205] and spu-
tum samples [206]. Recently, genetic variants of IL-6R have
been linked with lung function [207] and COPD severity
[208]. In contrast to elevated IL-6R levels in sputum of
COPD patients [207], the levels of sIL-6R in BALF from CF
patients were not diﬀerent in comparison to control, possibly
due to enhanced degradation of sIL-6R by serine proteases
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Figure 6: Classic and trans IL-6R signaling. In “classic” signaling membrane-bound IL-6R stimulated by secreted IL-6 associates with a
homodimer of signal transducing glycoprotein (gp130) to activate downstream signaling molecules, including the ubiquitous transcription
factor STAT-3. In trans-signaling, the soluble form of IL-6R (sIL-6R,) generated either by ADAM17 or by alternative mRNA splicing,
binds to IL-6 and this IL-6/IL-6R complex activates gp130 on the airway epithelial cells (autocrine IL-6R trans-signaling) or underlying
ﬁbroblasts, myoblasts, or smooth muscle cells that do not express IL-6R (paracrine IL-6R trans-signaling), but do express gp130 to evoke
activation of STAT-3 signaling.
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[209]. Furthermore, it is not evident what the impact of
luminal IL-6R on the activity of the subepithelial tissue
is, which is separated from the lumen by tight junctions.
Shedding of IL-6R from epithelial cells occurs mainly
towards the basal side where it can engage in paracrine
and autocrine signaling (Figure 6) [4, 87]. Inhibition of
sIL-6R by intraperitoneal injection of a recombinant decoy
receptor (gp130Fc) attenuates pulmonary ﬁbrosis, whereas
activation of IL-6 trans-signaling in cell lines enhances ﬁbro-
blast proliferation and extracellular matrix protein produc-
tion [210], which are the hallmarks of the pulmonary
ﬁbrosis progression.
Together, these data show the importance of IL-6R trans-
signaling in inﬂammation and lung remodeling and oﬀer
possibilities for therapeutic interventions [14].
8.1. Species Speciﬁcity of IL-6R Signaling. Murine models
have been invaluable in the study of inﬂammatory disease,
but should be analyzed with caution. Species diﬀerences in
IL-6R mediated signaling have been observed. Human IL-6
stimulates human and murine cells, whereas murine IL-6
only stimulates murine IL-6R signaling [211]. Because of
this species speciﬁcity, transgenic mice expressing human
sIL-6R from a liver promoter did not bind the endogenous
murine IL-6, and as a consequence the transgenic animals
do not have a transgene speciﬁc phenotype [211, 212].
Garbers et al. reported that human IL-6R is a substrate
of human ADAM17, but murine IL-6R is a substrate of
murine ADAM10 [213]. However, Schumacher et al. subse-
quently revealed that trigger-induced shedding of both
human and mouse IL-6R is mediated by murine ADAM17,
but constitutive release of IL-6R is largely mediated by
mADAM10 in mice [190]. Additionally, in humans, but
not in mice, the sIL-6R can be generated by translation
from an alternatively spliced mRNA [190, 214]. Of note,
the soluble gp130 form, which circulates in human plasma,
blocks IL-6R trans-signaling responses and does not show
species speciﬁcity, meaning that it interacts with human
and mouse sIL-6R complexes [215]. All of this has impli-
cations in the extrapolation of IL-6R data obtained in
mouse models to human, but is consistent with a promi-
nent role of EGFR/ADAM17 sIL-6R trans-signaling in
human lung pathology.
8.2. Dual Control of the STAT3 Transcription Pathway by the
EGFR/ADAM17 Axis. IL-6R-mediated signaling leads to acti-
vation of the transcription factor STAT3 [216], ERK [217],
and PI3K [201], linking this signaling pathway with the
EGFR/ADAM17 axis. STAT3 is also activated through a par-
allel pathway in trans-signaling, which involves shed EGFR
ligands [218](Figure 7). The STAT3 pathway is involved in
tissue repair [198], carcinogenesis [9, 219], and immune
responses [220]. Notably, STAT3 was found to be a modiﬁer
gene of cystic ﬁbrosis lung disease [221], and enhanced
STAT3 phosphorylation was observed in lung tissue from
smokers and COPD patients [222]. Consequently, a distur-
bance in the control of the complex EGFR/ADAM17/STAT3
pathway would likely play a role in Cystic Fibrosis and COPD
chronic lung disease.
9. ADAM17 Phosphorylation and Trafficking
The serine- and threonine-rich ADAM17 cytoplasmic tail
[112] has three phosphorylation sites that have been pro-
posed to activate ADAM17: Thr735, Ser791, and Ser819
(Figure 2). Pro-ADAM17 and mature ADAM17 are phos-
phorylated at Thr735 under resting conditions, but phorbol
ester (PMA) treatment further increases phosphorylation at
this site [223]. ERK 1/2 and p38 MAP kinase phosphorylate
ADAM17 at Thr735 [126: Diaz-Rodriguez, 2002 #237]
[224], and activate ADAM17 proteolytic activity, leading to
shedding of IL-6R and TGF-alpha [126]. Stimulation of
ADAM17 increases its phosphorylation without changing
the total protein level, suggesting that phosphorylation
plays a role in the regulation of the proteolytic activity of
ADAM17. However, mutation of the phosphorylation sites
individually or in combination and even removal of the
whole cytoplasmic tail has no signiﬁcant eﬀect on stimu-
lated shedding in cell models, suggesting that phosphoryla-
tion may be a minor regulatory mechanism of ADAM17
proteolytic activity, or that it plays a context and cell type
dependent role in intracellular transport, processing, and
maturation [112, 121, 225–227].
9.1. The Role of ADAM17, AREG/IL-6R, and EGFR
Traﬃcking in Cellular Signaling. The majority of EGFR sig-
naling is believed to occur at the plasma membrane. How-
ever, many studies show that upon ligand-dependent
activation, EGFR is rapidly internalized into endosomes,
where hypothetically it may continue to signal [228, 229].
Up till now, the triggered endocytosis of EGFR has been
interpreted as signal attenuation, due to lysosomal degrada-
tion [230]. However, recent reviews elaborate on the role of
EGFR endocytosis and recycling in active signal transduc-
tion [10, 230–233]. How triggered intracellular traﬃcking
of EGFR relates to the regulation of the EGFR/ADAM17
axis has not been explained in detail. So far, these studies
largely focus on deregulated EGFR traﬃcking in the con-
text of carcinogenesis. However, EGFR traﬃcking in CFTR
deﬁciency and its eﬀect on the signaling cascade has not
been investigated.
Most reports assume that ADAM17 cleaves and sheds it
substrates at the extracellular membrane. However, ADAMs
and its substrates have been localized in various subcellular
compartments like lysosomes [234], endosomes [175, 235],
and exosomes [233]; thus, it is diﬃcult to identify an exact
site of ADAM17mediated shedding and how it interacts with
EGFR [236].
Doedens et al. proposed that endocytosis from the cell
surface is a pre-requisite for ADAM17 catalytic activity
[237]. Lorenzen et al. suggested that ADAM17 and its sub-
strate meet in the ER/Golgi pathway and that the prodomain
does not interfere with the enzyme-substrate interaction
[100]. Xu et al. showed that ADAM17 is localized at the cell
surface as a dimer and associates with tissue inhibitor of
metalloproteinase-3 (TIMP-3) [126]. Upon activation with
PMA or anisomycin, the amount of ADAM17 at the cell sur-
face increases, followed by dissociation of ADAM17 from
TIMP-3, and ADAM17 dimers convert to monomers.
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According to the authors, these monomers correspond to the
active form of ADAM17 and are predominantly found in
cytoplasm [147], suggesting that the monomers are internal-
ized, and shedding may occur intracellularly. Also, recent
reports suggest that ADAM-mediated cleavage occurs from
an intracellular vesicular pool in several cell types. Triggered
shedding of FasL by ADAM10 and ADAM17 by T-
lymphocytes involves traﬃcking of proteases and substrates
to an intracellular membrane raft compartment [234]. More-
over, two proteins that regulate ADAM17-dependent shed-
ding of EGFR ligands, annexins, and a phosphofurin acidic
cluster sorting protein 2 are close to ADAM17 in the intracel-
lular vesicular compartment [235] as shown by proximity
ligation assay (PLA). Consistent with this, we have shown
by PLA that upon CS exposure ADAM17 and ADAM17-P
appear in close proximity with its substrates AREG and IL-
6R in the intracellular compartment in ALI-HBEC, whereas
under basal condition ADAM17 or ADAM17-P substrate
complexes were infrequent [87]. Together, reports from var-
ious cellular models suggest that the shedding process may
occur in an intracellular compartment and that triggered
activity involves active traﬃcking of ADAM17 and its sub-
strates. It remains to be established whether ADAM17
sheds its substrate in intracellular vesicles followed by
secretion or whether the ADAM17/substrate complexes in
these vesicles need to be transported to the membrane ﬁrst
in order to deliver ADAM17 and its substrate for cleavage.
In both cases, a vesicle traﬃcking and membrane fusion
event is involved, which may be subject to regulation, adding
another level of complexity.
A further aspect of the relationship between EGFR/
ADAM17 signaling and membrane traﬃcking concerns the
production and intercellular exchange of exosomes. Higgin-
botham et al. showed the importance of paracrine exosomal
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Figure 7: ADAM17/EGFR signaling an important player in CF and COPD lung disease. In airway epithelial cells in culture, both CFTR
deﬁciency [61] and cigarette smoke exposure [87] cause enhanced activity of the EGFR/ADAM17 signaling cascade, and thus enhanced
release of proinﬂammatory cytokines and growth factors that are ADAM17 substrates and signaling molecules that are downstream of the
EGFR/MAPK pathway (Figure 1) including the proinﬂammatory CXCL8 (IL-8). In chronic lung disease, this could contribute to mucous
metaplasia, inﬂammation, and tissue remodeling. A potential link between CFTR deﬁciency, COPD, and EGFR/ADAM17 activity (dashed
arrows) is the extracellular redox potential, which is in part dependent on CFTR-related glutathione transport [30, 165, 166], and which in
turn regulates ADAM17 activity (Figure 5). In COPD, CS induced long-term downregulation of CFTR expression [16, 47, 80] can have
the same long-term eﬀect, in addition to the acute oxidative stress caused by cigarette smoke. In this ﬁgure, we focus on two canonical
ADAM17 substrates: proinﬂammatory IL-6 receptor (IL-6R) and growth factor amphiregulin (AREG). AREG is proteolytically cleaved by
ADAM17 from airway epithelial cells and activates EGFR in the airway epithelial cells and on the underlying ﬁbroblasts. IL-6R trans-
signaling requires ADAM17-mediated shedding of the extracellular domain or alternative mRNA splicing. The soluble sIL-6R binds to IL-
6 creating IL-6/sIL-6R complexes that trans-activate gp130 on the underlying myoﬁbroblasts and myeloid cells. Signals transduced by
AREG and IL-6R shed from airway epithelial cells converge in combined activation of the transcription factor STAT3 in myoﬁbroblasts
and smooth muscle cells. STAT3 is involved in ﬁbrotic responses and inﬂammatory lung disease, and a modiﬁer of CF lung disease [221].
Based on available literature cited in text, enhanced EGFR/ADAM17 signaling may contribute to hyperinﬂammation and epithelial
metaplasia, ﬁbroblast and smooth muscle cell activation, angiogenesis, and net deposition of extracellular matrix (tissue remodeling)
observed in COPD and CF lung disease.
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AREG-mediated signaling in breast cancer cells [233].
Recipient LM2-4175 cells rapidly take up AREG-containing
exosomes in an EGFR-dependent manner and enhanced
invasion of LM2-4175 cells through matrigel [233]. Also,
EGFR- and ADAM17-containing exosomes have been
described [238, 239]. Such exosomes are considered impor-
tant in the resolution of tissue injury and inﬂammation,
presumably because they allow delivery of functional sig-
naling complexes from triggered cells to neighboring cells.
While most available studies address the role of exosomes
in the progression of cancer, their role in chronic lung dis-
ease and possible implications for future treatment is under
study [240].
10. Summary and Conclusions
Several lines of evidence, discussed above, suggest that the
ADAM17/EGFR axis and downstream regulatory pathways
are hyperactive in CF and COPD chronic lung disease, pro-
moting inﬂammation and tissue remodeling by shedding
EGFR binding growth factors and proinﬂammatory agonists
from airway epithelial cells. This may contribute to inﬂam-
mation, epithelial metaplasia, ﬁbroblast and smooth mus-
cle cell activation, and net deposition of extracellular
matrix. Taken together, we propose that pathology-driven
trans-signaling at least in part depends on airway epithelial
AREG and IL-6R shedding. Importantly, signals trans-
duced by shed AREG and IL-6R from airway epithelial
cells may converge in activation of the transcription factor
STAT3 in lung ﬁbroblasts, myoﬁbroblasts, and smooth
muscle cells (Figure 7). Moreover, unbalanced ligand shed-
ding towards the submucosa in CF and COPD and likely
other chronic lung disease will aﬀect the activity of resident
and inﬁltrating myeloid cells, including dendritic cells, mac-
rophages, and neutrophils.
While evidence in cellular and animals models is compel-
ling, direct evidence for EGFR/ADAM17 hyperactivity from
patient lung tissue in situ is scarce. This is in part due to a lack
of appropriate airway material for analysis, especially from
early disease and healthy controls. In a recent study, Zuo
et al. show enhanced AREG expression in biopsies from
smokers lungs, associated with remodeling lesions [181],
consistent with enhanced EGFR activity as shown in primary
cells in culture [87, 181]. However, successful pharmacologi-
cal interventions in the EGFR/ADAM17 pathway have not
been reported to our knowledge. Activation of CFTR activity
may help to reduce EGFR/ADAM17 activity and resolve
COPD pathology [85], but no clinical evidence for this is
yet available. Targeting EGFR/ADAM17 in CF patients has
not been attempted. Conversely, it would be important to
study patients treated with CFTR-targeted medication for
evidence of reduced activity of the EFGR/ADAM17 axis in
biomarker and biopsy studies.
Genetic analysis of the COPD and CF populations, aim-
ing at identiﬁcation of genes that determine the pathology
(“modiﬁer genes”) would also provide important evidence
for the involvement of the EGFR/ADAM17 axis. So far, as
already cited above, STAT3, controlled by the EGFR/
ADAM17 axis (Figure 7), is a modiﬁer of CF lung disease
[221]. IL-6R, a prominent ADAM17 substrate linking the
axis to STAT3 in trans-signaling, is a modiﬁer of COPD as
well as asthma [207, 208]. So far, polymorphisms associated
with the ADAM17, AREG, or EGFR genes have not been
directly linked to chronic lung disease, but that may be due
to limitations of the studies.
A possible mechanistic link between EGFR/ADAM17
activity, CF, and COPD is suggested by the observation that
CFTR activity is diminished in COPD airways. Reduced
CFTR activity interferes with glutathione transport in CF air-
ways, adding to oxidative stress, which would activate the
EGFR/ADAM17 axis both on CF and COPD. Further studies
in vivo and in vitro are required to establish this.
Interventions in the EGFR/ADAM17 pathway may
reduce CF and COPD lung pathology. However, since long-
term systemic delivery of available EGFR and ADAM17
inhibitors likely causes undesirable side eﬀects, novel
methods to control this pathways will likely be required.
Studies of stress-induced dynamic traﬃcking of the mem-
brane proteins involved in the EGFR/ADAM17 axis in
advanced 3D airway culture models may allow the develop-
ment of novel modulators that will allow a more targeted
approach to suit the requirements for treatment of CF and
COPD lung disease.
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